Ascelia Pharma to present at Redeye seminar in Malmö on 12 September 2019

2019-09-11

On 12th of September, Ascelia Pharma’s CEO Magnus Corfitzen will present the latest development in the company at Redeye’s afterwork event in Malmö. The presentation will be held at Clarion Hotel & Congress Malmö Live and Ascelia Pharma will start its presentation at 6pm CET.

The presentation can also be followed live via: https://www.redeye.se/live/inv-aw-malmo-12-9

Program and registration for the event can be found here: https://www.redeye.se/events#/event/583611


For more information, please contact:
Mikael Widell, IR & Communications Manager
Email: mw@ascelia.com
Tel: +46 703 11 99 60

The information was submitted for publication, through the agency of the contact person set out above, at 9.15am CET on 11 September 2019.

About Ascelia Pharma
Ascelia Pharma is an oncology-dedicated orphan drug development company located in Malmö, Sweden. The company’s strategy is to develop drugs, which target unmet medical needs, have an established mode of action and a relatively low development risk. Ascelia Pharma has two drug candidates – Mangoral® and Oncoral – currently under development.

Mangoral is a novel contrast agent for MR-scans and is ready for Phase III clinical studies. Mangoral is developed to improve the visualization of focal liver lesions (liver metastases) in patient with impaired kidneys that cannot tolerate current gadolinium contrast agents on the market. Oncoral is an oral chemotherapy tablet ready for Phase II for the treatment of gastric cancer. Ascelia Pharma is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit http://www.ascelia.com.

Download as PDF

2019-11-14

Bulletin from the Annual General Meeting in Ascelia Pharma AB on 14 November 2019

Today, on 14 November 2019, an annual general meeting was held in Ascelia Pharma AB. A summary of the adopted resolutions follows below. All resolutions were adopted with the required majority.
2019-11-08

Q1 2019/2020 Financial Report: Preparations for Phase III study with Mangoral® on track

Ascelia Pharma AB (publ) (ticker: ACE) today published its first quarter interim report for the period July 2019 – September 2019, which is now available on the company’s website: https://www.ascelia.com/tag/reports-presentations/
2019-10-25

Change in Ascelia Pharma’s management team

Ascelia Pharma AB (publ) today announced that Ascelia Pharma and the company’s Chief Operation Officer (COO) Dorthe da Graça Thrige have reached an agreement that she will be leaving the company. Her duties will be divided between other senior employees in Ascelia Pharma.